Last Updated: September 28, 2026

Acrotech Biopharma Company Profile

✉ Email this page to a colleague

« Back to Dashboard

What is the competitive landscape for ACROTECH BIOPHARMA

ACROTECH BIOPHARMA has six approved drugs.

There are twelve US patents protecting ACROTECH BIOPHARMA drugs.

Summary for Acrotech Biopharma

US Patents:	12
Tradenames:	6
Ingredients:	6
NDAs:	6

Drugs and US Patents for Acrotech Biopharma

+ Get email alerts for changes to this table

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Acrotech Biopharma	FUSILEV	levoleucovorin calcium	POWDER;INTRAVENOUS	020140-001	Mar 7, 2008		DISCN	Yes	No		⤷ Start Trial				⤷ Start Trial
Acrotech Biopharma	FUSILEV	levoleucovorin calcium	SOLUTION;INTRAVENOUS	020140-002	Apr 29, 2011		DISCN	Yes	No		⤷ Start Trial				⤷ Start Trial
Acrotech Biopharma	EVOMELA	melphalan hydrochloride	POWDER;INTRAVENOUS	207155-001	Mar 10, 2016		RX	Yes	Yes	11,020,363	⤷ Start Trial	Y			⤷ Start Trial
Acrotech Biopharma	EVOMELA	melphalan hydrochloride	POWDER;INTRAVENOUS	207155-001	Mar 10, 2016		RX	Yes	Yes	9,200,088	⤷ Start Trial	Y			⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for Acrotech Biopharma

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Acrotech Biopharma	FOLOTYN	pralatrexate	SOLUTION;INTRAVENOUS	022468-002	Sep 24, 2009	8,299,078	⤷ Start Trial
Acrotech Biopharma	FOLOTYN	pralatrexate	SOLUTION;INTRAVENOUS	022468-001	Sep 24, 2009	7,622,470	⤷ Start Trial
Acrotech Biopharma	BELEODAQ	belinostat	POWDER;INTRAVENOUS	206256-001	Jul 3, 2014	6,888,027	⤷ Start Trial
Acrotech Biopharma	FUSILEV	levoleucovorin calcium	SOLUTION;INTRAVENOUS	020140-002	Apr 29, 2011	6,500,829	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Paragraph IV (Patent) Challenges for ACROTECH BIOPHARMA drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Injection	50 mg/vial	➤ Subscribe	2017-09-08
➤ Subscribe	Injection	50 mg/vial	➤ Subscribe	2013-12-19
➤ Subscribe	Injection	500 mg/vial	➤ Subscribe	2018-07-03
➤ Subscribe	Injection	10 mg/mL, 17.5 mL vial and 25 mL vial	➤ Subscribe	2011-10-26
➤ Subscribe	Injection	20 mg/mL and 40 mg/2 mL	➤ Subscribe	2013-09-24

International Patents for Acrotech Biopharma Drugs

Subscribe to access the full database, or Start Trial
Country	Patent Number	Estimated Expiration
Japan	4976354	⤷ Start Trial
Israel	243654	⤷ Start Trial
Spain	2540204	⤷ Start Trial
Philippines	12015500887	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration

Supplementary Protection Certificates for Acrotech Biopharma Drugs

Subscribe to access the full database, or Start Trial
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2701720	SPC/GB23/004	United Kingdom	⤷ Start Trial	PRODUCT NAME: MELPHALAN FLUFENAMIDE HYDROCHLORIDE; REGISTERED: UK EU/1/22/1669/001(NI) 20220818; UK MORE ON HISTORY TAB 20220818
2701720	3/2023	Austria	⤷ Start Trial	PRODUCT NAME: MELPHALANFLUFENAMID-HYDROCHLORID; REGISTRATION NO/DATE: EU/1/22/1669 (MITTEILUNG) 20220818
2701720	CR 2022 00054	Denmark	⤷ Start Trial	PRODUCT NAME: MELPHALAN FLUFENAMIDE HYDROCHLORIDE; REG. NO/DATE: EU/1/22/1669 20220818
2701720	202240050	Slovenia	⤷ Start Trial	PRODUCT NAME: MELPHALAN FLUFENAMIDE HYDROCHLORIDE; NATIONAL AUTHORISATION NUMBER: EU/1/22/1669/001; DATE OF NATIONAL AUTHORISATION: 20220817; AUTHORITY FOR NATIONAL AUTHORISATION: EU
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.